EVT 302 is an orally active, potent, highly selective and reversible inhibitor of MAO-B. It is in the development for smoking cessation, and potential for disease modification in Alzheimer's disease.
- Mechanism
- Curator reviewed
EVT 302 is used in smoking cessation. It is a reversible and highly selective inhibitor of monoamine oxidase B (MAO-B). MAOs are enzymes involved in the catabolism of monoamine neurotransmitters, such as dopamine, serotonin, and norephinephrine. Cigarette smoking produces inhibition of brain MAO activity in humans. Since monoamines are involved in the reinforcing and rewarding effects of tobacco smoking, the use of MAO inhibitors (MAOIs) has been proposed as a treatment for tobacco dependence.
- Primary indication
- Investigated for use/treatment in smoking cessation.Curator reviewed
- Code names
- EVT 302
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with EVT 302, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account